Fibrocell Science Inc (FCSC)

[1millman]

Glaxo Smith Kline could be a potential deep pocket partner with the connections that CEO Pernock has there.


David Pernock, Chairman of the Board and CEO, joined Fibrocell Science with extensive leadership experience in healthcare sales and commercialization, building business units, partnerships, and brands, most recently as senior vice president, Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care and HIV at GlaxoSmithKline. Over a long career at GlaxoSmithKline, Mr. Pernock was promoted numerous times to levels of increasing responsibility including vice president of Marketing, Pharmaceuticals; vice president of Sales and Marketing, Oncology; vice president of Managed Care; and, vice president of Sales. Mr. Pernock holds a BS in Business Administration from Arizona State University. He serves on many philanthropic organizations.